Welcome to our dedicated page for Kyverna Therapeutics SEC filings (Ticker: KYTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kyverna Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kyverna Therapeutics's regulatory disclosures and financial reporting.
Kyverna Therapeutics, Inc. Executive Chairperson Christi Shaw reported a routine tax-related share disposition. On May 27, 2026, 4,194 shares of common stock were withheld and surrendered to the company to cover tax withholding obligations arising from a restricted stock unit (RSU) vesting.
The footnote explains this was tied to an RSU award for 16,634 shares that vested in full on May 27, 2026. After the tax-withholding transaction, Shaw directly holds 66,741 shares of Kyverna Therapeutics common stock.
Kyverna Therapeutics director Aktar Mert reported equity awards consisting of restricted stock units and stock options. The filing shows a grant of 5,093 shares of Common Stock as restricted stock units that vest in full on the earlier of May 27, 2027, or immediately before the company’s 2027 annual stockholder meeting, if service continues through that date. Mert also received stock options covering 20,582 shares of Common Stock at an exercise price of $8.59 per share, which become fully vested and exercisable on the same timeline. Following the restricted stock grant, Mert holds 21,727 shares of Common Stock directly.
Kyverna Therapeutics, Inc. reported that Chief Financial Officer Gregory S. Martini received a grant of stock options covering 325,000 shares of common stock. The options have an exercise price of $8.54 per share and expire on May 18, 2036. One quarter of the option grant vests on May 18, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on his continuous service. Following this compensation-related award, Martini holds 325,000 derivative securities directly, with no open-market purchases or sales reported in this filing.
Kyverna Therapeutics, Inc. filed a Form 3 identifying Gregory S. Martini as a reporting person in his role as Chief Financial Officer. The filing does not list any share purchases, sales, acquisitions, dispositions, or derivative exercises, and shows no reported holdings or derivative positions.
Kyverna Therapeutics, Inc. appointed Gregory (Greg) Martini as Chief Financial Officer, effective May 18, 2026, succeeding Marc Grasso, M.D., who will remain as a strategic advisor through August 1, 2026 to support a smooth transition. Martini becomes Kyverna’s principal financial and accounting officer.
Under his offer letter, Martini receives a $525,000 base salary, an annual bonus opportunity equal to 40% of salary (pro‑rated for 2026), and a $300,000 sign‑on bonus, split into two $150,000 payments tied to his start date and first anniversary. He will also be granted a stock option to purchase 325,000 shares of common stock under Kyverna’s 2024 Inducement Equity Incentive Plan, vesting over four years, along with severance and change‑in‑control protections.
Kyverna states that Grasso’s transition is not due to any disagreement over operations or financial reporting. The accompanying press release highlights Martini’s prior CFO role at Ironwood Pharmaceuticals and frames his hire as supporting Kyverna’s evolution into a commercial‑stage company as it advances its CAR T‑cell therapy candidate miv‑cel toward potential approval in autoimmune diseases.
Kyverna Therapeutics initiated a rolling biologics license application (BLA) submission for its CAR T-cell therapy miv-cel in stiff person syndrome (SPS) after a positive pre-BLA meeting with the FDA confirming that the single-arm KYSA-8 trial can support the filing and potential priority review under its RMAT designation. The company reported robust, durable SPS data with all patients off immunotherapies through last follow-up, and encouraging results across generalized myasthenia gravis and progressive multiple sclerosis programs.
For the quarter ended March 31, 2026, Kyverna reported a net loss of $39.7 million, or $0.66 per share, on operating expenses of $41.4 million. Cash, cash equivalents and marketable securities were $236.4 million, and management continues to expect a cash runway into 2028 while advancing launch readiness for a potential SPS commercial rollout.
Kyverna Therapeutics granted Chief Commercial Officer Nadia Dac a stock option to acquire 300,000 shares of common stock at an exercise price of $9.00 per share, expiring on May 4, 2036. This is a compensation award, not an open-market share purchase.
One quarter of the option vests on May 4, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months, contingent on her continuous service with the company.
Kyverna Therapeutics, Inc. filed a Form 3 identifying Nadia Dac as a reporting person in her role as Chief Commercial Officer. This Form 3 serves as an initial statement of insider status for SEC reporting. The provided data show no reported share purchases, sales, or other transactions in this filing.
Kyverna Therapeutics, Inc. appointed veteran commercial leader Nadia Dac as Chief Commercial Officer, effective May 4, 2026. She will lead commercial strategy and execution for miv-cel (mivocabtagene autoleucel, KYV-101), a CD19-targeting CAR T-cell therapy being developed for stiff person syndrome and other B‑cell-driven autoimmune diseases.
In connection with her appointment, Kyverna will grant Ms. Dac an option to purchase 300,000 shares of common stock under its Amended and Restated 2024 Inducement Equity Incentive Plan, as an inducement award under Nasdaq Listing Rule 5635(c)(4). The option will have an exercise price equal to the closing price on May 4, 2026 and will vest over four years, with 25% vesting on the one-year anniversary of her appointment and the remainder vesting in equal monthly installments thereafter, subject to continued service.